Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Fate Therapeutics (FATE) over the last 13 years, with Q3 2025 value amounting to $115.3 million.

  • Fate Therapeutics' Shares Outstanding rose 127.48% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year increase of 127.48%. This contributed to the annual value of $113.9 million for FY2024, which is 1551.42% up from last year.
  • As of Q3 2025, Fate Therapeutics' Shares Outstanding stood at $115.3 million, which was up 127.48% from $114.7 million recorded in Q2 2025.
  • Fate Therapeutics' 5-year Shares Outstanding high stood at $115.3 million for Q3 2025, and its period low was $93.9 million during Q1 2021.
  • Over the past 5 years, Fate Therapeutics' median Shares Outstanding value was $98.5 million (recorded in 2023), while the average stood at $103.2 million.
  • Its Shares Outstanding has fluctuated over the past 5 years, first soared by 2354.41% in 2021, then skyrocketed by 70.74% in 2025.
  • Over the past 5 years, Fate Therapeutics' Shares Outstanding (Quarter) stood at $95.7 million in 2021, then rose by 1.64% to $97.3 million in 2022, then rose by 1.37% to $98.6 million in 2023, then grew by 15.51% to $113.9 million in 2024, then grew by 1.24% to $115.3 million in 2025.
  • Its Shares Outstanding was $115.3 million in Q3 2025, compared to $114.7 million in Q2 2025 and $114.6 million in Q1 2025.